Está usando un navegador no compatible.
Es posible que algunas características de este sitio no funcionen correctamente. Para tener una experiencia de usuario óptima, vea este sitio en Chrome, Firefox, Safari o Edge.

Congresos y publicaciones

Materiales de congresos

Acceda a resúmenes, pósteres y presentaciones en inglés de los siguientes congresos

Junio 2023

EHA (Asociación Europea de Hematología)

EHA (Asociación Europea de Hematología)

June 2023 (Frankfurt, Germany)

Resúmenes

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies BGB-16673, a BTK degrader, overcomes on-target resistance from BTK inhibitors and presents sustainable long-term tumor regression in lymphoma xenograft models Bruton tyrosine kinase (BTK) protein degrader BGB-16673 is less apt to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors (BTKi) Characterization of zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database Comparative efficacy of zanubrutinib (zanu) versus rituximab (rtx) in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC) Efficacy and safety of once daily (QD) vs twice daily (BID) zanubrutinib for patients with various B-cell malignancies: a comparative summary of clinical data and exposure-response analysis First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): results from the phase 3 ASPEN trial long-term follow-up Long-term efficacy and safety of zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Matching-adjusted indirect comparison (MAIC) of zanubrutinib (zanu) versus ibrutinib (ibru) in relapsed/refractory marginal zone lymphoma (R/R MZL) Persistent with oral therapy as reflection of actual compliance for chronic lymphocytic leukemia (CLL) - a national prescribed drug and patient registered study from Sweden Real-world treatment patterns of Bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) in community oncology practices in the United States (US) The meta-analytic endpoint validation of surrogates used in clinical trials evaluating the efficacy of therapies in patients with chronic lymphocytic leukemia Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Junio 2023

ASCO (Sociedad Estadounidense de Oncología Clínica)

ASCO (Sociedad Estadounidense de Oncología Clínica)

Junio de 2023 (Chicago, Illinois, EE. UU.)

Resúmenes

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC) Comparative efficacy of zanubrutinib (ZANU) versus rituximab (RTX) in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC) First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS) MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL) Real-world treatment patterns of Bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) in community oncology practices in the United States (US) Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): the RATIONALE-301 European/North American (EU/NA) subgroup Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a Phase Ib/II study Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Mayo 2023

ISPOR (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)

Abril 2023

BSH (Sociedad Británica de Hematología)

BSH (Sociedad Británica de Hematología)

April 2023 (Birmingham, England)
Abril 2023

AACR (Asociación Estadounidense de Investigación en Cáncer)

AACR (Asociación Estadounidense de Investigación en Cáncer)

Abril de 2023 (Orlando, Florida, EE. UU.)
Marzo 2023

SFH (Sociedad Francesa de Hematología)

SFH (Sociedad Francesa de Hematología)

Marzo 2023 (París, Francia)

Publicaciones más recientes

Imagen de banner con molécula azul y roja Su capacidad para acceder a estos artículos puede depender de su suscripción o la de su institución a las revistas.

Buscar publicaciones y materiales de congresos

Este sitio web alberga una base de datos de publicaciones y materiales de congresos médicos de todo el mundo. Utilice nuestro motor de búsqueda a continuación para acceder a la información según sus necesidades de búsqueda.

BeiGene, Ltd. mantiene el sitio para su información personal, educación y comunicación. No dude en explorar el sitio. Sin embargo, usted no puede distribuir, modificar, transmitir, reutilizar, volver a publicar o usar el contenido del sitio para fines públicos o comerciales, incluidos los textos e imágenes, sin el permiso por escrito de BeiGene.  
 
Este es un recurso médico en línea para obtener información científica y clínica. BeiGene no garantiza que la información de este sitio sea adecuada para cada país o región. Si decide acceder a este sitio, usted es responsable de cumplir con las leyes locales aplicables. 

Parte del contenido solo está disponible en inglés.

Powered by Translations.com GlobalLink OneLink Software